Effect of intermittent fasting on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease
Liu Q, Zhang L, Wang Y, Li J, Li Y
Clinics and research in hepatology and gastroenterology · 1 cita
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2026-06-29 · Clin Res Hepatol Gastroenterol · vol. 50 · número 7 · pág. 102875
- Editorial
- Elsevier BV
- Citado
- 2 citas · más que el 98% de estudios similares · 10.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 73 trabajos
- Acceso
- De pago
- Áreas de investigación
- Dietary Effects on Health · Diet and metabolism studies · Liver Disease Diagnosis and Treatment
- Palabras clave
- Steatosis, Liver steatosis, Fatty liver, Intermittent fasting, Liver disease, Disease
- MeSH
- humans, fatty liver, fasting, non-alcoholic fatty liver disease, intermittent fasting
5 autores
- Qinhan Liu🇨🇳Southwest Medical University; Affiliated Hospital of Southwest Medical University
- Ling Zhang🇨🇳Southwest Medical University; Affiliated Hospital of Southwest Medical University
- Yaomin Wang🇨🇳Southwest Medical University; Affiliated Hospital of Southwest Medical University
- Jun Li🇨🇳 · autor de correspondenciaSouthwest Medical University
- Yaling Li🇨🇳 · autor de correspondenciaSouthwest Medical University; Affiliated Hospital of Southwest Medical University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously called non-alcoholic fatty liver disease (NAFLD), is marked by hepatic steatosis. While intermittent fasting (IF) lowers weight and lipids in obesity, its effect on MASLD-related liver fat remains unclear.
Methods
We searched the databases including PubMed, Cochrane Library, Web of Science, and Embase to find studies for inclusion in the meta-analysis. The Review Manager 5.3 and Stata 17.0 were used to perform the meta-analysis, and the results were reported as mean difference (MD) or standardized mean difference (SMD), along with their 95% confidence intervals (CIs).
Results
Finally, eight studies with 389 subjects were included. Meta-analysis showed that: 1) IF significantly improved liver fat content (MD = -3.01, 95% CI [-5.84, -0.18]; P = 0.04) and controlled attenuation parameter (CAP) in patients with MASLD (MD = -18.64, 95% CI [-30.29, -6.99]; P = 0.002). 2) IF reduced body weight, body mass index (BMI), and triglycerides (TG) in Patients with MASLD, and the differences were statistically significant (P < 0.05).
Conclusion
IF improves hepatic steatosis in MASLD, suggesting a potential to modify disease progression. However, rigorous multicenter randomized trials are required to confirm these findings and develop evidence-based clinical strategies for MASLD management.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.